In consultation: Guidance and quality standards
Showing 1 to 2 of 2
Title | Consultation | Type | Consultation end date |
---|---|---|---|
Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342] | Draft guidance | Technology appraisal guidance | |
Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333] | Draft guidance | Technology appraisal guidance |